ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

ClinicalTrials.gov ID: NCT04270760

Public ClinicalTrials.gov record NCT04270760. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)

Study identification

NCT ID
NCT04270760
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
281 participants

Conditions and interventions

Interventions

  • Olpasiran Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 27, 2020
Primary completion
Dec 26, 2021
Completion
Nov 7, 2022
Last update posted
Mar 30, 2026

2020 – 2022

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Westside Medical Associates of Los Angeles Beverly Hills California 90211
Excel Medical Clinical Trials Boca Raton Florida 33434
Piedmont Healthcare Atlanta Georgia 30309
University of Kansas Medical Center Kansas City Kansas 66160
Johns Hopkins Baltimore Maryland 21287
New York University New York New York 10016
Mount Sinai Hospital New York New York 10029
Columbia University Medical Center New York New York 10032
Crossroads Clinical Research Inc Mooresville North Carolina 28117
Cleveland Clinic Cleveland Ohio 44195
Baylor College of Medicine Houston Texas 77030
Protenium Clinical Research Hurst Texas 76054

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04270760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04270760 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →